Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra treatment in TRAPS
2006-001927-20Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jun 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in TNF receptor-associated periodic syndrome (TRAPS) and familial amyloidosis, sponsored by Istituto Giannina Gaslini. Primary endpoints: Reduction in acute phase reactants at 15 days, Reduction in acute phase reactants at 6 months and 4 more. Started Jun 2007; status: completed.
02
Drugs
anakinra
03
Conditions
TNF receptor-associated periodic syndrome (TRAPS)familial amyloidosis
Beyond the preview
Go deeper on 2006-001927-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001927-20.